Skip to main content
. Author manuscript; available in PMC: 2019 Jan 15.
Published in final edited form as: Cancer Res. 2017 Nov 27;78(2):451–462. doi: 10.1158/0008-5472.CAN-17-1803

Figure 5. Validation of TAp63 and ΔNp63 in independent cohorts.

Figure 5

a, Validation of corresponding TAp63 activities in independent cohorts of kidney clear cell (KIRC), kidney papillary (KIRP) and low grade glioma (LGG). b, Survival of KIRP in independent cohorts with respect to TAp63KIRP activity. c, Validation of corresponding ΔNp63 activities in independent cohorts of bladder cancer (BLCA), KIRC, KIRP and LGG. d, Survival of BLCA and KIRP in independent cohorts with respect to ΔNp63BLCA and ΔNp63KIRP activities, respectively. Number of cases in each group is listed between parenthesis where indicated.